AstraZeneca to launch Eculizumab (Soliris) in India in August

Bengaluru, August 6, 2025 — AstraZeneca Pharma India Ltd (NSE: ASTRAZEN / BSE: 506820) has announced that it will launch the Eculizumab (Soliris) in India in August 2025. The company received the import and market permission for it from the Drugs Controller General of India (DCGI) in January under Form CT-20.

Market Snapshot

As of August 6, 2025, the shares of AstraZeneca closed at ₹8,834.00, down by 0.24%. The shares recorded an intraday high of ₹8,892.00 and a low of ₹8,731.00, with a VWAP of ₹8,807.94.

About Eculizumab (Soliris)

Soliris is a monoclonal antibody therapy that is used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)and atypical Hemolytic Uremic Syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare blood disorders.

The drug helps the patient regulate the conditions by inhibiting complement-mediated thrombotic microangiopathy, which means that it blocks a part of the immune system that is overactive. As overactivity can damage small blood vessels and cause serious problems, stopping this process, the drug prevents further harm to the body and helps patients stay healthier.

Management Commentary

“We wish to further update that AstraZeneca Pharma India Limited will launch Eculizumab (Soliris) in August 2025 in India,” the company stated in a regulatory filing on Wednesday.

Strategic Outlook

The approval and upcoming launch of Soliris signals AstraZeneca’s entry into high-value rare disease therapy. The market views this as a push toward specialty biologics. Investors should track regulatory follow-through, pricing approvals, and potential revenue scale-up from India’s orphan drug segment.

About the Company

AstraZeneca Pharma India Limited, headquartered in Bengaluru, Karnataka, operates in the pharmaceutical industry. The company develops, manufactures, and markets medications across therapeutic areas such as cardiovascular, oncology, respiratory, and infection. Listed on Indian stock markets under the ticker ASTRAZEN, it works on bringing innovative prescription medicines to patients nationwide.

REF:https://nsearchives.nseindia.com/corporate/ASTRAZEN_06082025145929_Intimation_to_Stock_Exchanges_Soliris_launch.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations